A genomic approach to human autoimmune diseases

Annual Review of Immunology

Volumn 28, Issue , 2010, Pages 535-571

  Pascual, Virginia ^a   Chaussabel, Damien ^a   Banchereau, Jacques ^a,b  

^a BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarkers; Blood; Juvenile arthritis; Lupus; Microarray

Indexed keywords

INTERFERON; INTERLEUKIN 6; TRANSCRIPTOME; BIOLOGICAL MARKER;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; DIABETES MELLITUS; DISEASE ACTIVITY; DNA MICROARRAY; DNA SEQUENCE; GENE EXPRESSION; GENOME; GENOMICS; HEMATOLOGIC MALIGNANCY; HUMAN; INNATE IMMUNITY; JUVENILE RHEUMATOID ARTHRITIS; MEDICINE; MULTIPLE SCLEROSIS; MYOSITIS; PATHOGENESIS; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; QUANTITATIVE ANALYSIS; REVIEW; RHEUMATOID ARTHRITIS; RNA SEQUENCE; SAMPLE SIZE; SJOEGREN SYNDROME; SOLID TUMOR; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; ANIMAL; BLOOD; GENETICS; HIGH THROUGHPUT SCREENING; IMMUNOLOGY;

ANIMALS; AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; GENOMICS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 77952318708     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev-immunol-030409-101221     Document Type: Review

References (198)

1. Davis MM. 2008. A prescription for human immunology. Immunity 29:835-838
2. Liu K, Mohan C. 2006. What do mouse models teach us about human SLE? Clin. Immunol. 119:123-130
3. Horai R, Saijo S, Tanioka H, Nakae S, Sudo K, et al. 2000. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J. Exp. Med. 191:313-320
4. MertensM, Singh JA. 2009. Anakinra for rheumatoid arthritis:asystematic review. J. Rheumatol. 36:1118-1125
5. Feldmann M, Maini RN. 2001. Anti-TNFα therapy of rheumatoid arthritis: What have we learned? Annu. Rev. Immunol. 19:163-196
6. Schena M, Shalon D, Davis RW, Brown PO. 1995. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270:467-470
7. Shalon D, Smith SJ, Brown PO. 1996. A DNA microarray system for analyzing complex DNA samples using two-color fluorescent probe hybridization. Genome Res. 6:639-645
8. Wang Z, Gerstein M, Snyder M. 2009. RNA-Seq: a revolutionary tool for transcriptomics. Nat. Rev. Genet. 10:57-63
9. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, et al. 1999. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286:531-537
10. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, et al. 2000. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511
11. Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, et al. 2006. Gene expression profiling of primary cutaneous melanoma and clinical outcome. J. Natl. Cancer Inst. 98:472-482
12. Sotiriou C, Pusztai L. 2009. Gene-expression signatures in breast cancer. N. Engl. J. Med. 360:790-800
13. Pascual V, Allantaz F, Patel P, Palucka AK, Chaussabel D, Banchereau J. 2008. How the study of children with rheumatic diseases identified interferon-α and interleukin-1 as novel therapeutic targets. Immunol. Rev. 223:39-59
14. Bauer JW, Bilgic H, Baechler EC. 2009. Gene-expression profiling in rheumatic disease: tools and therapeutic potential. Nat. Rev. Rheumatol. 5:257-265
15. Calvano SE, Xiao W, Richards DR, Felciano RM, Baker HV, et al. 2005. A network-based analysis of systemic inflammation in humans. Nature 437:1032-1037
16. Zaas AK, Chen M, Varkey J, Veldman T, Hero AO, et al. 2009. Gene expression signatures diagnose influenza and other symptomatic respiratory viral infections in humans. Cell Host Microbe 6:207-217
17. Boldrick JC, Alizadeh AA, Diehn M, Dudoit S, Liu CL, et al. 2002. Stereotyped and specific gene expression programs in human innate immune responses to bacteria. Proc. Natl. Acad. Sci. USA 99:972-977
18. Cookson W, Liang L, Abecasis G, Moffatt M, Lathrop M. 2009. Mapping complex disease traits with global gene expression. Nat. Rev. Genet. 10:184-194
19. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. 2005. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med. 201:1479-1486
20. Wang X, Jia S, Geoffrey R, Alemzadeh R, Ghosh S, Hessner MJ. 2008. Identification of a molecular signature in human type 1 diabetes mellitus using serum and functional genomics. J. Immunol. 180:1929-1937
21. Bennett L, Palucka AK, ArceE, Cantrell V, BorvakJ, et al. 2003. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197:711-723
22. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, et al. 2003. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. USA 100:2610-2615
23. Crow MK, Wohlgemuth J. 2003. Microarray analysis of gene expression in lupus. Arthritis Res. Ther. 5:279-287
24. Han GM, Chen SL, Shen N, Ye S, Bao CD, Gu YY. 2003. Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray. Genes Immun. 4:177-186
25. Allantaz F, Chaussabel D, Stichweh D, Bennett L, Allman W, et al. 2007. Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. J. Exp. Med. 204:2131-2144
26. Ogilvie EM, Khan A, Hubank M, Kellam P, Woo P. 2007. Specific gene expression profiles in systemic juvenile idiopathic arthritis. Arthritis Rheum. 56:1954-1965
27. Fall N, Barnes M, Thornton S, Luyrink L, Olson J, et al. 2007. Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. Arthritis Rheum. 56:3793-3804
28. Barnes MG, Grom AA, Thompson SD, Griffin TA, Pavlidis P, et al. 2009. Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis. Arthritis Rheum. 60:2102-2112
29. AchironA, FeldmanA, MandelM, GurevichM. 2007. Impaired expressionofperipheral blood apoptotic-related gene transcripts in acute multiple sclerosis relapse. Ann. N. Y. Acad. Sci. 1107:155-167
30. Singh MK, Scott TF, LaFramboise WA, Hu FZ, Post JC, Ehrlich GD. 2007. Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing beta-interferon therapy. J. Neurol. Sci. 258:52-59
31. Edwards CJ, Feldman JL, Beech J, Shields KM, Stover JA, et al. 2007. Molecular profile of peripheral blood mononuclear cells from patients with rheumatoid arthritis. Mol. Med. 13:40-58
32. Van Der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Voskuyl AE, Rustenburg F, et al. 2007. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann. Rheum. Dis. 66:1008-1014
33. Lequerre T, Gauthier-Jauneau AC, Bansard C, Derambure C, Hiron M, et al. 2006. Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis. Arthritis Res. Ther. 8:R105
34. Batliwalla FM, Baechler EC, Xiao X, Li W, Balasubramanian S, et al. 2005. Peripheral blood gene expression profiling in rheumatoid arthritis. Genes Immun. 6:388-397
35. Emamian ES, Leon JM, Lessard CJ, Grandits M, Baechler EC, et al. 2009. Peripheral blood gene expression profiling in Sjogren's syndrome. Genes Immun. 10:285-296
36. Kaizer EC, Glaser CL, Chaussabel D, Banchereau J, Pascual V, White PC. 2007. Gene expression in peripheral blood mononuclear cells from children with diabetes. J. Clin. Endocrinol. Metab. 92:3705-3711
37. Takamura T, Honda M, Sakai Y, Ando H, Shimizu A, et al. 2007. Gene expression profiles in peripheral blood mononuclear cells reflect the pathophysiology of type 2 diabetes. Biochem. Biophys. Res. Commun. 361:379-384
38. Burczynski ME, Peterson RL, Twine NC, Zuberek KA, Brodeur BJ, et al. 2006. Molecular classification of Crohn's disease and ulcerative colitis patients using transcriptional profiles in peripheral blood mononuclear cells. J. Mol. Diagn. 8:51-61
39. Stoeckman AK, Baechler EC, Ortmann WA, Behrens TW, Michet CJ, Peterson EJ. 2006. A distinct inflammatory gene expression profile in patients with psoriatic arthritis. Genes Immun. 7:583-591
40. Batliwalla FM, Li W, Ritchlin CT, Xiao X, Brenner M, et al. 2005. Microarray analyses of peripheral blood cells identifies unique gene expression signature in psoriatic arthritis. Mol. Med. 11:21-29
41. Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D, et al. 2005. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann. Neurol. 57:664-678
42. Baechler EC, Bauer JW, Slattery CA, Ortmann WA, Espe KJ, et al. 2007. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol. Med. 13:59-68
43. Tan FK, Zhou X, Mayes MD, Gourh P, Guo X, et al. 2006. Signatures of differentially regulated interferon gene expression and vasculotrophisminthe peripheral blood cellsof systemic sclerosis patients. Rheumatology (Oxford) 45:694-702
44. York MR, Nagai T, Mangini AJ, Lemaire R, van Seventer JM, Lafyatis R. 2007. A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and Toll-like receptor agonists. Arthritis Rheum. 56:1010-1020
45. Alcorta DA, Barnes DA, Dooley MA, Sullivan P, Jonas B, et al. 2007. Leukocyte gene expression signatures in antineutrophil cytoplasmic autoantibody and lupus glomerulonephritis. Kidney Int. 72:853-864
46. Potti A, Bild A, Dressman HK, Lewis DA, Nevins JR, Ortel TL. 2006. Gene-expression patterns predict phenotypes of immune-mediated thrombosis. Blood 107:1391-1396
47. Lempicki RA, Polis MA, Yang J, McLaughlin M, Koratich C, et al. 2006. Gene expression profiles in hepatitis C virus (HCV) and HIV coinfection: class prediction analyses before treatment predict the outcome of anti-HCV therapy among HIV-coinfected persons. J. Infect. Dis. 193:1172-1177
48. Thach DC, Agan BK, Olsen C, Diao J, Lin B, et al. 2005. Surveillance of transcriptomes in basic military trainees with normal, febrile respiratory illness, and convalescent phenotypes. Genes Immun. 6:588-595
49. Popper SJ, Watson VE, Shimizu C, Kanegaye JT, Burns JC, Relman DA. 2009. Gene transcript abundance profiles distinguish Kawasaki disease from adenovirus infection. J. Infect. Dis. 200:657-666
50. Ramilo O, Allman W, Chung W, Mejias A, Ardura M, et al. 2007. Gene expression patterns in blood leukocytes discriminate patients with acute infections. Blood 109:2066-2077
51. Simmons CP, Popper S, Dolocek C, Chau TN, Griffiths M, et al. 2007. Patterns of host genome-wide gene transcript abundance in the peripheral blood of patients with acute dengue hemorrhagic fever. J. Infect. Dis. 195:1097-1107
52. Ardura MI, Banchereau R, Mejias A, Di Pucchio T, Glaser C, et al. 2009. Enhanced monocyte response and decreased central memory T cells in children with invasive Staphylococcus aureus infections. PLoS One 4:e5446
53. Jacobsen M, Repsilber D, Gutschmidt A, Neher A, Feldmann K, et al. 2007. Candidate biomarkers for discrimination between infection and disease caused by Mycobacterium tuberculosis. J. Mol. Med. 85:613-621
54. Ockenhouse CF, Hu WC, Kester KE, Cummings JF, Stewart A, et al. 2006. Common and divergent immune response signaling pathways discovered in peripheral blood mononuclear cell gene expression patterns in presymptomatic and clinically apparent malaria. Infect. Immun. 74:5561-5573
55. Tang BM, McLean AS, Dawes IW, Huang SJ, Lin RC. 2007. The use of gene-expression profiling to identify candidate genes in human sepsis. Am. J. Respir. Crit. Care Med. 176:676-684
56. Zhang HQ, Lu H, Enosawa S, Takahara S, Sakamoto S, Suzuki S. 2002. Identification of novel genes associated with immunosuppression in renal transplant patients. Transplant. Proc. 34:2733-2735
57. Martinez-Llordella M, Puig-Pey I, Orlando G, Ramoni M, Tisone G, et al. 2007. Multiparameter immune profiling of operational tolerance in liver transplantation. Am. J. Transplant. 7:309-319
58. Deng MC, Eisen HJ, Mehra MR, Billingham M, Marboe CC, et al. 2006. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am. J. Transplant. 6:150-160
59. Baron C, Somogyi R, Greller LD, Rineau V, Wilkinson P, et al. 2007. Prediction of graft-versus-host disease in humans by donor gene-expression profiling. PLoS Med. 4:e23
60. Tang Y, Xu H, Du X, Lit L, Walker W, et al. 2006. Gene expression in blood changes rapidly in neutrophils and monocytes after ischemic stroke in humans: a microarray study. J. Cereb. Blood Flow Metab. 26:1089-1102
61. Solmi R, Ugolini G, Rosati G, Zanotti S, Lauriola M, et al. 2006. Microarray-based identification and RT-PCR test screening for epithelial-specific mRNAs in peripheral blood of patients with colon cancer. BMC Cancer 6:250
62. Osman I, Bajorin DF, Sun TT, Zhong H, Douglas D, et al. 2006. Novel blood biomarkers of human urinary bladder cancer. Clin. Cancer Res. 12:3374-3380
63. Llorente L, Zou W, Levy Y, Richaud-Patin Y, Wijdenes J, et al. 1995. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J. Exp. Med. 181:839-844
64. Llorente L, Richaud-Patin Y, Garcia-Padilla C, Claret E, Jakez-Ocampo J, et al. 2000. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum. 43:1790-1800
65. Yokoyama H, Takabatake T, Takaeda M, Wada T, Naito T, et al. 1992. Up-regulated MHC-class II expression and γ-IFN and soluble IL-2R in lupus nephritis. Kidney Int. 42:755-763
66. Haas C, Ryffel B, Le Hir M. 1997. IFN-γ is essential for the development of autoimmune glomeru-lonephritis in MRL/Ipr mice. J. Immunol. 158:5484-5491
67. Horwitz DA, Gray JD, Behrendsen SC, Kubin M, Rengaraju M, et al. 1998. Decreased production of interleukin-12 and other Th1-type cytokines in patients with recent-onset systemic lupus erythematosus. Arthritis Rheum. 41:838-844
68. Steinberg AD, Baron S, Talal N. 1969. The pathogenesis of autoimmunity in New Zealand mice, I. Induction of antinucleic acid antibodies by polyinosinic-polycytidylic acid. Proc. Natl. Acad. Sci. USA 63:1102-1107
69. Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL. 1979. Immune interferon in the circulation of patients with autoimmune disease. N. Engl. J. Med. 301:5-8
70. Stewart TA. 2003. Neutralizing interferon alpha as a therapeutic approach to autoimmune diseases. Cytokine Growth Factor Rev. 14:139-154
71. Cederblad B, Blomberg S, Vallin H, Perers A, Alm GV, Ronnblom L. 1998. Patients with systemic lupus erythematosus have reduced numbers of circulating natural interferon-α-producing cells. J. Autoimmun. 11:465-470
72. Blomberg S, Eloranta ML, Cederblad B, Nordlin K, Alm GV, Ronnblom L. 2001. Presenceofcutaneous interferon-a producing cells in patients with systemic lupus erythematosus. Lupus 10:484-490
73. Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen FL. 2001. Plasmacytoid dendritic cells (natural interferon-α/β-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am. J. Pathol. 159:237-243
74. Vallin H, Blomberg S, Alm GV, Cederblad B, Ronnblom L. 1999. Patients with systemic lupus erythe-matosus (SLE) have a circulating inducer of interferon-alpha (IFN-α) production acting on leucocytes resembling immature dendritic cells. Clin. Exp. Immunol. 115:196-202
75. Bave U, Vallin H, Alm GV, Ronnblom L. 2001. Activation of natural interferon-α producing cells by apoptotic U937 cells combined with lupus IgG and its regulation by cytokines. J. Autoimmun. 17:71-80
76. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. 2001. Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus. Science 294:1540-1543
77. Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J. 2003. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 19:225-234
78. Marrack P, Kappler J, Mitchell T. 1999. Type I interferons keep activated T cells alive. J. Exp. Med. 189:521-530
79. Kolumam GA, Thomas S, Thompson LJ, Sprent J, Murali-Krishna K. 2005. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J. Exp. Med. 202:637-650
80. Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DF. 2001. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14:461-470
81. Preble OT, Black RJ, Friedman RM, Klippel JH, Vilcek J. 1982. Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon. Science 216:429-431
82. Tsao BP. 2004. Update on human systemic lupus erythematosus genetics. Curr. Opin. Rheumatol. 16:513-521
83. Darnell JE Jr, Kerr IM, Stark GR. 1994. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:1415-1421
84. Martinelli S, Urosevic M, Daryadel A, Oberholzer PA, Baumann C, et al. 2004. Induction of genes mediating interferon-dependent extracellular trap formation during neutrophil differentiation. J. Biol. Chem. 279:44123-44132
85. de Weerd NA, Samarajiwa SA, Hertzog PJ. 2007. Type Iinterferon receptors: biochemistry and biological functions. J. Biol. Chem. 282:20053-20057
86. de Veer MJ, Holko M, Frevel M, Walker E, Der S, et al. 2001. Functional classification of interferon-stimulated genes identified using microarrays. J. Leukoc. Biol. 69:912-920
87. Ding C. 2008. Belimumab, an anti-BLyS human monoclonal antibody for potential treatment of inflammatory autoimmune diseases. Expert Opin. Biol. Ther. 8:1805-1814
88. Shodell M, Shah K, Siegal FP. 2003. Circulating human plasmacytoid dendritic cells are highly sensitive to corticosteroid administration. Lupus 12:222-230
89. Peterson KS, Huang JF, Zhu J, D'Agati V, Liu X, et al. 2004. Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli. J. Clin. Invest. 113:1722-1733
90. Nzeusseu Toukap A, Galant C, Theate I, Maudoux AL, Lories RJ, et al. 2007. Identification of distinct gene expression profiles in the synovium of patients with systemic lupus erythematosus. Arthritis Rheum. 56:1579-1588
91. Tucci M, Quatraro C, Lombardi L, Pellegrino C, Dammacco F, Silvestris F. 2008. Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18. Arthritis Rheum. 58:251-262
92. Gill MA, Blanco P, Arce E, Pascual V, Banchereau J, Palucka AK. 2002. Blood dendritic cells and DC-poietins in systemic lupus erythematosus. Hum. Immunol. 63:1172-1180
93. Santiago-Raber ML, Baccala R, Haraldsson KM, Choubey D, Stewart TA, et al. 2003. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J. Exp. Med. 197:777-788
94. Braun D, Geraldes P, Demengeot J. 2003. Type I interferon controls the onset and severity of autoimmune manifestations in lpr mice. J. Autoimmun. 20:15-25
95. 1 but not in BALB/c Mice. J. Immunol. 174:2499-2506
96. Zagury D, Le Buanec H, Mathian A, Larcier P, Burnett R, et al. 2009. IFNα kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model. Proc. Natl. Acad. Sci. USA 106:5294-5299
97. Izui S, Ibnou-Zekri N, Fossati-Jimack L, Iwamoto M. 2000. Lessons from BXSB and related mouse models. Int. Rev. Immunol. 19:447-472
98. Pisitkun P, Deane JA, Difilippantonio MJ, Tarasenko T, Satterthwaite AB, Bolland S. 2006. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 312:1669-1672
99. Subramanian S, Tus K, Li QZ, Wang A, Tian XH, et al. 2006. A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. Proc. Natl. Acad. Sci. USA 103:9970-9975
100. Bave U, Alm GV, Ronnblom L. 2000. The combination of apoptotic U937 cells and lupus IgG is a potent IFN-α inducer. J. Immunol. 165:3519-3526
101. Vollmer J, Tluk S, Schmitz C, Hamm S, Jurk M, et al. 2005. Immune stimulation mediated byautoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J. Exp. Med. 202:1575-1585
102. Barrat FJ, Meeker T, Gregorio J, Chan JH, Uematsu S, et al. 2005. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J. Exp. Med. 202:1131-1139
103. Lau CM, Broughton C, Tabor AS, Akira S, Flavell RA, et al. 2005. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J. Exp. Med. 202:1171-1177
104. Deane JA, Pisitkun P, Barrett RS, Feigenbaum L, Town T, et al. 2007. Control of Toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation. Immunity 27:801-810
105. Kono DH, Haraldsson MK, Lawson BR, Pollard KM, Koh YT, et al. 2009. Endosomal TLR signaling is required for antinucleic acid and rheumatoid factor autoantibodies in lupus. Proc. Natl. Acad. Sci. USA 106:12061-12066
106. Armstrong DL, Reiff A, Myones BL, Quismorio FP Jr, Klein-Gitelman M, et al. 2009. Identification of new SLE-associated genes with a two-step Bayesian study design. Genes Immun. 10:446-456
107. Sigurdsson S, Nordmark G, Goring HH, Lindroos K, Wiman AC, et al. 2005. Polymorphisms in the ty-rosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am. J. Hum. Genet. 76:528-537
108. Graham RR, Kozyrev SV, Baechler EC, Reddy MV, Plenge RM, et al. 2006. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat. Genet. 38:550-555
109. Harley JB, Alarcon-Riquelme ME, Criswell LA, Jacob CO, Kimberly RP, et al. 2008. Genome-wide association scaninwomen with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat. Genet. 40:204-210
110. Niewold TB, Kelly JA, Flesch MH, Espinoza LR, Harley JB, Crow MK. 2008. Association of the IRF5 risk haplotype with high serum interferon-α activity in systemic lupus erythematosus patients. Arthritis Rheum. 58:2481-2487
111. Niewold TB, Hua J, Lehman TJ, Harley JB, CrowMK. 2007. High serum IFN-a activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun. 8:492-502
112. Remmers EF, Plenge RM, Lee AT, Graham RR, Hom G, et al. 2007. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N. Engl. J. Med. 357:977-986
113. Jacob CO, Reiff A, Armstrong DL, Myones BL, Silverman E, et al. 2007. Identification of novel susceptibility genes in childhood-onset systemic lupus erythematosus using a uniquely designed candidate gene pathway platform. Arthritis Rheum. 56:4164-4173
114. Jacob CO, Zhu J, Armstrong DL, YanM, Han J, et al. 2009. Identification of IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus. Proc. Natl. Acad. Sci. USA 106:6256-6261
115. Rice G, Newman WG, Dean J, Patrick T, Parmar R, et al. 2007. Heterozygous mutations in TREX1 cause familial chilblain lupus and dominant Aicardi-Goutieres syndrome. Am. J. Hum. Genet. 80:811-815
116. Lee-Kirsch MA, Gong M, Chowdhury D, Senenko L, Engel K, et al. 2007. Mutations in the gene encoding the 3'-5' DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat. Genet. 39:1065-1067
117. Stetson DB, Ko JS, Heidmann T, Medzhitov R 2008. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 134:587-598
118. Lehtinen DA, Harvey S, MulcahyMJ, HollisT, PerrinoFW. 2008. TheTREX1 double-stranded DNA degradation activity is defective in dominant mutations associated with autoimmune disease. J. Biol. Chem. 283:31649-31656
119. Tal MC, Sasai M, Lee HK, Yordy B, Shadel GS, Iwasaki A. 2009. Absence of autophagy results in reactive oxygen species-dependent amplification of RLR signaling. Proc. Natl. Acad. Sci. USA 106:2770-2775
120. Moser KL, Kelly JA, Lessard CJ, Harley JB. 2009. Recent insights into the genetic basis of systemic lupus erythematosus. Genes. Immun. 10:373-379
121. PaluckaAK, BlanckJP, Bennett L, Pascual V, BanchereauJ. 2005. Cross-regulation ofTNF and IFN-a in autoimmune diseases. Proc. Natl. Acad. Sci. USA 102:3372-3377
122. Arce E, Jackson DG, Gill MA, Bennett LB, Banchereau J, Pascual V. 2001. Increased frequency of pregerminal center B cells and plasma cell precursors in the blood of children with systemic lupus erythematosus. J. Immunol. 167:2361-2369
123. Odendahl M, Jacobi A, Hansen A, Feist E, Hiepe F, et al. 2000. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J. Immunol. 165:5970-5979
124. Wrammert J, Smith K, Miller J, Langley WA, Kokko K, et al. 2008. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453:667-671
125. Yao Y, Richman L, Higgs BW, Morehouse CA, de los Reyes M, et al. 2009. Neutralization of interferon-a/|3-inducible genes and downstream effect in a phase I trial of an anti-interferon-a monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum. 60:1785-1796
126. Prieur AM, Roux-Lombard P, Dayer JM. 1996. Dynamics of fever and the cytokine network in systemic juvenile arthritis. Rev. Rhum. (Engl. Ed.) 63:163-170
127. Muller K, Herner EB, Stagg A, Bendtzen K, Woo P. 1998. Inflammatory cytokines and cytokine antagonists in whole blood cultures of patients with systemic juvenile chronic arthritis. Br. J. Rheumatol. 37:562-569
128. Fitzgerald AA, Leclercq SA, Yan A, Homik JE, Dinarello CA. 2005. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum. 52:1794-1803
129. Dinarello CA. 1996. Biologic basis for interleukin-1 in disease. Blood 87:2095-2147
130. Wittkowski H, Frosch M, Wulffraat N, Goldbach-Mansky R, Kallinich T, et al. 2008. S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis Rheum. 58:3924-3931
131. Frosch M, Ahlmann M, Vogl T, Wittkowski H, Wulffraat N, et al. 2009. The myeloid-related proteins 8 and 14 complex, a novel ligand of Toll-like receptor 4, and interleukin-113 form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 60:883-891
132. Korman BD, Alba MI, Le JM, Alevizos I, Smith JA, et al. 2008. Variant form of STAT4 is associated with primary Sjogren's syndrome. Genes Immun. 9:267-270
133. Nordmark G, Kristjansdottir G, Theander E, Eriksson P, Brun JG, et al. 2009. Additive effects of the major risk alleles of IRF5 and STAT4 in primary Sjogren's syndrome. Genes Immun. 10:68-76
134. Hjelmervik TO, Petersen K, Jonassen I, Jonsson R, Bolstad AI. 2005. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjogren's syndrome patients from healthy control subjects. Arthritis Rheum. 52:1534-1544
135. Hu S, Wang J, Meijer J, Ieong S, Xie Y, et al. 2007. Salivary proteomic and genomic biomarkers for primary Sjogren's syndrome. Arthritis Rheum. 56:3588-3600 (Pubitemid 350100692)
136. Greenberg SA. 2007. A gene expression approach to study perturbed pathways in myositis. Curr. Opin. Rheumatol. 19:536-541
137. Arahata K, Engel AG. 1984. Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quan-titation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann. Neurol. 16:193-208
138. Wenzel J, Schmidt R, Proelss J, Zahn S, Bieber T, Tuting T. 2006. Type I interferon-associated skin recruitment of CXCR3+ lymphocytes in dermatomyositis. Clin. Exp. Dermatol. 31:576-582
139. Feldman BM, Rider LG, Reed AM, Pachman LM. 2008. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 371:2201-2212
140. *0501+ children with untreated dermatomyositis: a novel model of pathogenesis. J. Immunol. 168:4154-4163
141. Walsh RJ, Kong SW, Yao Y, Jallal B, Kiener PA, et al. 2007. Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum. 56:3784-3792
142. Lowes MA, Bowcock AM, Krueger JG. 2007. Pathogenesis and therapy of psoriasis. Nature 445:866-873
143. Oestreicher JL, Walters IB, Kikuchi T, Gilleaudeau P, Surette J, et al. 2001. Molecular classification of psoriasis disease-associated genes through pharmacogenomic expression profiling. Pharmacogenomics J. 1:272-287
144. Nomura I, Gao B, Boguniewicz M, Darst MA, Travers JB, Leung DY. 2003. Distinct patterns of gene expression in the skin lesions of atopic dermatitis and psoriasis: a gene microarray analysis. J. Allergy Clin. Immunol. 112:1195-1202
145. Bowcock AM, Shannon W, Du F, Duncan J, Cao K, et al. 2001. Insights into psoriasis and other inflammatory diseases from large-scale gene expression studies. Hum. Mol. Genet. 10:1793-1805
146. Zhou X, Krueger JG, Kao MC, Lee E, Du F, et al. 2003. Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63100-element oligonucleotide array. Physiol. Genomics 13:69-78
147. Imboden JB. 2009. The immunopathogenesis of rheumatoid arthritis. Annu. Rev. Pathol. 4:417-434
148. Devauchelle V, Marion S, Cagnard N, Mistou S, Falgarone G, et al. 2004. DNA microarray allows molecular profiling ofrheumatoid arthritis and identificationof pathophysiological targets. Genes Immun. 5:597-608
149. Van Der Pouw Kraan TC, van Gaalen FA, Kasperkovitz PV, Verbeet NL, Smeets TJ, et al. 2003. Rheumatoid arthritis is a heterogeneous disease: evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues. Arthritis Rheum. 48:2132-2145
150. Van Der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Rustenburg F, Baggen JM, et al. 2008. Responsiveness to antitumor necrosis factor α therapy is related to pretreatment tissue inflammation levels in rheumatoid arthritis patients. Ann. Rheum. Dis. 67:563-566
151. Gabrielli A, Avvedimento EV, Krieg T. 2009. Scleroderma. N. Engl. J. Med. 360:1989-2003
152. Milano A, Pendergrass SA, Sargent JL, George LK, McCalmont TH, et al. 2008. Molecular subsets in the gene expression signatures of scleroderma skin. PLoS One 3:e2696
153. Bos CL, van Baarsen LG, Timmer TC, Overbeek MJ, Basoski NM, et al. 2009. Molecular subtypes of systemic sclerosis in association with anticentromere antibodies and digital ulcers. Genes. Immun. 10:210-218
154. Rueda B, Broen J, Simeon C, Hesselstrand R, Diaz B, et al. 2009. The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype. Hum. Mol. Genet. 18:2071-2077
155. Frohman EM, Racke MK, Raine CS. 2006. Multiple sclerosis-the plaque and its pathogenesis. N. Engl. J. Med. 354:942-955
156. Mycko MP, Papoian R, Boschert U, Raine CS, Selmaj KW. 2003. cDNA microarray analysis in multiple sclerosis lesions: detection of genes associated with disease activity. Brain 126:1048-1057
157. Mycko MP, Papoian R, Boschert U, Raine CS, Selmaj KW. 2004. Microarray gene expression profiling of chronic active and inactive lesions in multiple sclerosis. Clin. Neurol. Neurosurg. 106:223-229
158. Iglesias AH, Camelo S, Hwang D, Villanueva R, Stephanopoulos G, Dangond F. 2004. Microarray detection of E2F pathway activation and other targets in multiple sclerosis peripheral blood mononuclear cells. J. Neuroimmunol. 150:163-177
159. Satoh J, Nakanishi M, Koike F, Miyake S, Yamamoto T, et al. 2005. Microarray analysis identifies an aberrant expression of apoptosis and DNA damage-regulatory genes in multiple sclerosis. Neurobiol. Dis. 18:537-550
160. Koike F, Satoh J, Miyake S, Yamamoto T, Kawai M, et al. 2003. Microarray analysis identifies interferon beta-regulated genes in multiple sclerosis. J. Neuroimmunol. 139:109-118
161. Sturzebecher S, Wandinger KP, Rosenwald A, Sathyamoorthy M, Tzou A, et al. 2003. Expression profiling identifies responder and nonresponder phenotypes to interferon-beta in multiple sclerosis. Brain 126:1419-1429
162. Pappas DJ, Coppola G, Gabatto PA, Gao F, Geschwind DH, et al. 2009. Longitudinal system-based analysis of transcriptional responses to type I interferons. Physiol. Genomics 38:362-371
163. Huang X, Yuang J, Goddard A, Foulis A, James RF, et al. 1995. Interferon expression in the pancreases of patients with type I diabetes. Diabetes 44:658-664
164. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, et al. 2007. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 356:1517-1526
165. Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T. 2009. Sustained effects of interleukin-1-receptor antagonist treatment in type 2
166. Cassidy JT, Petty RE. 2001. Juvenile rheumatoid arthritis. In Textbook of Pediatric Rheumatology, ed. JT Cassidy, RE Petty, pp. 218-321. Philadelphia: W. B. Saunders. 3rd ed.
167. Chaussabel D, Allman W, Mejias A, Chung W, Bennett L, et al. 2005. Analysis of significance patterns identifies ubiquitous and disease-specific gene-expression signatures in patient peripheral blood leukocytes. Ann. N. Y. Acad. Sci. 1062:146-154
168. Mootha VK, Bunkenborg J, Olsen JV, Hjerrild M, Wisniewski JR, et al. 2003. Integrated analysis of protein composition, tissue diversity, and gene regulation in mouse mitochondria. Cell 115:629-640
169. Segal E, Yelensky R, Koller D. 2003. Genome-wide discovery of transcriptional modules from DNA sequence and gene expression. Bioinformatics 19(Suppl. 1):i273-82
170. Allison DB, Cui X, Page GP, Sabripour M. 2006. Microarray data analysis: from disarray to consolidation and consensus. Nat. Rev. Genet. 7:55-65
171. Horvath S, Dong J. 2008. Geometric interpretation of gene coexpression network analysis. PLoS Comput. Biol. 4:e1000117
172. Chaussabel D, Quinn C, Shen J, Patel P, Glaser C, et al. 2008. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity 29:150-164
173. Liang MH, Socher SA, Larson MG, Schur PH. 1989. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum. 32:1107-1118
174. Gladman DD, Ibanez D, Urowitz MB. 2002. Systemic lupus erythematosus disease activity index 2000. J. Rheumatol. 29:288-291
175. Snyder M, Weissman S, Gerstein M. 2009. Personal phenotypes to go with personal genomes. Mol. Syst. Biol. 5:273
176. Whitney AR, Diehn M, Popper SJ, Alizadeh AA, Boldrick JC, et al. 2003. Individuality and variation in gene expression patterns in human blood. Proc. Natl. Acad. Sci. USA 100:1896-1901
177. Debey S, Zander T, Brors B, Popov A, Eils R, Schultze JL. 2006. A highly standardized, robust, and cost-effective method for genome-wide transcriptome analysis of peripheral blood applicable to large-scale clinical trials. Genomics 87:653-664
178. Debey-Pascher S, Eggle D, Schultze JL. 2009. RNA stabilization of peripheral blood and profiling by bead chip analysis. Methods Mol. Biol. 496:175-210
179. Tian Z, Palmer N, Schmid P, Yao H, Galdzicki M, et al. 2009. A practical platform for blood biomarker study by using global gene expression profiling of peripheral whole blood. PLoS One 4:e5157
180. Vartanian K, Slottke R, Johnstone T, Casale A, Planck SR, et al. 2009. Gene expression profiling of whole blood: comparisonoftarget preparation methods for accurate and reproducible microarray analysis. BMC Genomics 10:2
181. Li L, Ying L, Naesens M, Xiao W, Sigdel T, et al. 2008. Interference of globin genes with biomarker discovery for allograft rejection in peripheral blood samples. Physiol. Genomics 32:190-197
182. Shi L, Reid LH, Jones WD, Shippy R, Warrington JA, et al. 2006. The MicroArray Quality Control (MAQC) project shows inter-and intraplatform reproducibility of gene expression measurements. Nat. Biotechnol. 24:1151-1161
183. Shi L, Perkins RG, Fang H, Tong W. 2008. Reproducible and reliable microarray results through quality control: good laboratory proficiency and appropriate data analysis practices are essential. Curr. Opin. Biotechnol. 19:10-18
184. Tan PK, Downey TJ, Spitznagel EL Jr, Xu P, Fu D, et al. 2003. Evaluation of gene expression measurements from commercial microarray platforms. Nucleic Acids Res. 31:5676-5684
185. Butte AJ, Kohane IS. 2006. Creation and implications of a phenome-genome network. Nat. Biotechnol. 24:55-62
186. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, et al. 2004. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc. Natl. Acad. Sci. USA 101:9309-9314
187. Boulesteix AL, Strobl C, Augustin T, Daumer M. 2008. Evaluating microarray-based classifiers: an overview. Cancer Inform. 6:77-97
188. Ancona N, Maglietta R, Piepoli A, D'Addabbo A, Cotugno R, et al. 2006. On the statistical assessment of classifiers using DNA microarray data. BMC Bioinform. 7:387
189. Fraser ID, Germain RN. 2009. Navigating the network: signaling cross-talk in hematopoietic cells. Nat. Immunol. 10:327-331
190. Zak DE, Aderem A. 2009. Systems biology of innate immunity. Immunol. Rev. 227:264-282
191. Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, et al. 2008. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat. Biotechnol. 26:317-325
192. Wold B, Myers RM. 2008. Sequence census methods for functional genomics. Nat. Methods 5:19-21
193. Sultan M, Schulz MH, Richard H, Magen A, Klingenhoff A, et al. 2008. A global view of gene activity and alternative splicing by deep sequencing of the human transcriptome. Science 321:956-960
194. Shilatifard A. 2006. Chromatin modifications by methylation and ubiquitination: implications in the regulation of gene expression. Annu. Rev. Biochem. 75:243-269
195. Martin DA, Elkon KB. 2005. Autoantibodies make a U-turn: the toll hypothesis for autoantibody specificity. J. Exp. Med. 202:1465-1469
196. Tian J, Avalos AM, Mao SY, Chen B, Senthil K, et al. 2007. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat. Immunol. 8:487-496
197. Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang YH, et al. 2007. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 449:564-569
198. Ganguly D, Chamilos G, Lande R, Gregorio J, Meller S, et al. 2009. Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J. Exp. Med. 206:1983-1994